联环药业(600513.SH)子公司盐酸林可霉素注射液通过仿制药一致性评价

Group 1 - Company Lianhuan Pharmaceutical (600513.SH) announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the supplemental application of Lincomycin Hydrochloride Injection [1] - The approved product, Lincomycin Hydrochloride Injection (specification: 2ml:0.6g), is classified as a lincosamide antibiotic, indicated for respiratory infections, skin and soft tissue infections, and bone and joint infections caused by sensitive bacteria [1] - According to the MoSheng Medical Database, the sales revenue of Lincomycin Hydrochloride Injection (specification: 2ml:0.6g) in domestic sample hospitals is projected to be 10.82 million yuan in 2024 [1]